825
Views
18
CrossRef citations to date
0
Altmetric
Original Article

Ustekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasis

, , &
Pages 113-120 | Received 03 Jan 2014, Accepted 04 Jan 2014, Published online: 20 Feb 2014

References

  • About Psoriasis. National Psoriasis Foundation. Available from http://www.psoriasis.org/learn_statistics. Accessed on November 14, 2011
  • Friedewald VE, Cather JC, Gelfand JM, et al. AJC’s editor consensus: psoriasis and coronary artery disease. Am J Cardiol. 2008;102:1631–43
  • Sterry W, Barker J, Boehncke WH, et al. Biologic therapies in the systemic management of psoriasis: international consensus conference. Brit J Dermatol. 2004;151:3–17
  • Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146:89–95
  • Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899–912
  • Stelara® (ustekinumab) prescribing information. Horsham, PA: Centocor Ortho Biotech Inc
  • Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83
  • Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075–9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.